View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports

Fulgent Genetics Inc: 1 director

A director at Fulgent Genetics Inc sold 22,000 shares at 26.521USD and the significance rating of the trade was 62/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cl...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

 PRESS RELEASE

Fulgent Genetics to Announce First Quarter 2021 Financial Results on T...

Fulgent Genetics to Announce First Quarter 2021 Financial Results on Thursday May 6, 2021 TEMPLE CITY, Calif., April 16, 2021 (GLOBE NEWSWIRE) -- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”), a technology company providing comprehensive testing solutions through its scalable technology platform, today announced that it will release its first quarter 2021 financial results after the market closes on Thursday May 6, 2021. The company’s Chairman and Chief Executive Officer Ming Hsieh, Chief Financial Officer Paul Kim and Chief Commercial Officer Brandon Perthui...

 PRESS RELEASE

Fulgent Genetics Awarded Contract from CDC to Study Variants of COVID-...

Fulgent Genetics Awarded Contract from CDC to Study Variants of COVID-19 Virus Agreement leverages Fulgent’s Next Generation Sequencing (“NGS”) capabilities for genomic sequencing to aid in ongoing research of SARS-CoV-2, the virus that causes COVID-19 TEMPLE CITY, Calif., March 15, 2021 (GLOBE NEWSWIRE) -- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “Company”), a technology company providing comprehensive testing solutions through its scalable platform, today announced that the U.S. Centers for Disease Control and Prevention (“CDC”) has awarded the Company a contra...

 PRESS RELEASE

Fulgent Genetics to Participate in the Oppenheimer 31st Annual Healthc...

Fulgent Genetics to Participate in the Oppenheimer 31st Annual Healthcare Conference TEMPLE CITY, Calif., March 05, 2021 (GLOBE NEWSWIRE) -- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”), a technology company providing comprehensive testing solutions through its scalable technology platform, today announced that its Chairman and Chief Executive Officer Ming Hsieh, Chief Financial Officer Paul Kim, and Chief Commercial Officer Brandon Perthuis are scheduled to virtually participate in the Oppenheimer 31st Annual Healthcare Conference on Tuesday, March 16, 2021...

 PRESS RELEASE

Fulgent Genetics Reports Record Fourth Quarter and Full Year 2020 Fina...

Fulgent Genetics Reports Record Fourth Quarter and Full Year 2020 Financial Results Fourth Quarter 2020 Results: Record Revenue of $295.0 million, growing more than 3,400% year-over-yearRecord Billable tests delivered approximately 3.2 million, approximately 230 times the volume of fourth quarter of 2019Gross Margin improved over 8 percentage points sequentially and approximately 26 percentage points year-over-year; cost per test improved approximately 36% sequentiallyNon-COVID Revenue grew 43% year-over-yearRecord GAAP income of $166.3 million, or $6.16 per shareRecord Non-GAAP income of ...

 PRESS RELEASE

Fulgent Genetics to Announce Fourth Quarter and Full Year 2020 Financi...

Fulgent Genetics to Announce Fourth Quarter and Full Year 2020 Financial Results on Thursday March 4, 2021 TEMPLE CITY, Calif., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”), a technology company providing comprehensive testing solutions through its scalable technology platform, today announced that it will release its fourth quarter and full year 2020 financial results after the market closes on Thursday March 4, 2021. The company’s Chairman and Chief Executive Officer Ming Hsieh, Chief Financial Officer Paul Kim and Chief C...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Booster Shots: Attractive bottom-fishing stocks

For investors looking for bottom-fishing candidates; stocks that are breaking downtrends, exhibiting ascending reaction lows, and showing stabilizing relative strength.

 PRESS RELEASE

Fulgent Genetics to Participate in the H.C. Wainwright BIOCONNECT 2021...

Fulgent Genetics to Participate in the H.C. Wainwright BIOCONNECT 2021 Conference TEMPLE CITY, Calif., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”), a technology company providing comprehensive testing solutions through its scalable technology platform, today announced that its Chief Financial Officer Paul Kim, and Chief Commercial Officer Brandon Perthuis are scheduled to virtually participate in a presentation at the H.C. Wainwright BIOCONNECT 2021 Conference taking place January 11 to 14, 2021. A webcast of the presentat...

 PRESS RELEASE

Fulgent Genetics Extends Partnership with New York City Test and Trace...

Fulgent Genetics Extends Partnership with New York City Test and Trace for COVID-19 Testing, Awarded Contract for 2021 School Year Following a competitive process, Fulgent was selected to extend its support of the NYC DOE public school testing managed by the NYC Test and Trace Corps with on-site staffing and RT-PCR tests through the remainder of the 2021 school year TEMPLE CITY, Calif., Dec. 29, 2020 (GLOBE NEWSWIRE) -- Fulgent Genetics (Nasdaq: FLGT), a technology company providing comprehensive testing solutions through its scalable technology platform, today announced that the Compan...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

OXY OCCIDENTAL PETROLEUM CORPORATION
XOMA XOMA
VRNT VERINT SYSTEMS INC.
TTGT TECHTARGET INC.
THC TENET HEALTHCARE CORPORATION
TGTX TG THERAPEUTICS INC.
SGMO SANGAMO THERAPEUTICS INC.
QIA QIAGEN NV
PERI PERION NETWORK LTD
OTIC OTONOMY
NVTA INVITAE CORP
NSTG NANOSTRING TECHNOLOGIES
LIVN LIVANOVA PLC
KURA KURA ONCOLOGY INC.
EDIT EDITAS MEDICINE INC.
DVN DEVON ENERGY CORPORATION
DHT DHT HOLDINGS INC.
DGII DIGI INTERNATIONAL INC.
CODI COMPASS DIVERSIFIED HOLDINGS
CDNA CAREDX INC
BLFS BIOLIFE SOLUTIONS INC
ARWR ARROWHEAD PHARMACEUTICALS INC.
AR ANTERO RESOURCES CORPORATION
APA.. APA CORP.
ALKS ALKERMES PLC
SLCA U.S. SILICA HOLDINGS INC.
MUR MURPHY OIL CORPORATION
JW.A JOHN WILEY & SONS INC. CLASS A
CLB CORE LABORATORIES NV
HOFT HOOKER FURNITURE CORP.
NRP NATURAL RESOURCE PARTNERS L.P.
OII OCEANEERING INTERNATIONAL INC.
PDCE PDC ENERGY INC.
PTEN PATTERSON-UTI ENERGY INC.
WFT.. WEATHERFORD INTERNATIONAL PLC
AA ALCOA CORPORATION
INSG INSEEGO CORP
NTLA INTELLIA THERAPEUTICS INC.
FLGT FULGENT GENETICS
SNAP SNAP INC. CLASS A
CNDT CONDUENT INC.
HCC WARRIOR MET COAL INC.
SOI SOLARIS OILFIELD INFRASTRUCTURE
MYOV MYOVANT SCIENCE
IOVA IOVANCE BIOTHERAPEUTICS INC
CARS CARS.COM INC.
CLF CLEVELAND-CLIFFS INC
CTRA ALPHA METALLURGICAL RESOURCES INC.
DESP DESPEGAR.COM CORP.
CNX CNX RESOURCES CORPORATION
MDB MONGODB INC. CLASS A
CEIX CONSOL ENERGY INC
CDLX CARDLYTICS INC
AVYA AVAYA HOLDINGS
SURF SURFACE ONCOLOGY
MGY MAGNOLIA OIL & GAS CORP. CLASS A
LTHM LIVENT
STNG SCORPIO TANKERS INC.
TPTX TURNING POINT THERAPEUTICS
DSSI DIAMOND S SHIPPING
TUFN TUFIN SOFTWARE TECHNOLOGIES
PHR PHREESIA
TNK TEEKAY TANKERS
NET CLOUDFLARE INC CLASS A
AHCO ADAPTHEALTH
PSNL PERSONALIS
TWST TWIST BIOSCIENCE
AM ANTERO MIDSTREAM CORP.
GOCO GOHEALTH
LPI INC.
IAC LAREDO PETROLEUM INC.
ARCH IAC/INTERACTIVECORP.
CPE ARCH RESOURCES INC. CLASS A
NBR CALLON PETROLEUM
BEAM NABORS INDUSTRIES LTD.
ADPT BEAM THERAPEUTICS
ADAPTIVE BIOTECHNOLOGIES
Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

 PRESS RELEASE

Fulgent Genetics to Participate in the Piper Sandler 32nd Annual Healt...

Fulgent Genetics to Participate in the Piper Sandler 32nd Annual Healthcare Conference TEMPLE CITY, Calif., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”), a technology company providing comprehensive testing solutions through its scalable technology platform, today announced that its Chairman and Chief Executive Officer Ming Hsieh, Chief Financial Officer Paul Kim, and Chief Commercial Officer Brandon Perthuis virtually participated in a pre-recorded fireside chat that will be published as part of the Piper Sandler 32nd Annua...

 PRESS RELEASE

Fulgent Genetics Announces Increase to Full Year 2020 Guidance to $300...

Fulgent Genetics Announces Increase to Full Year 2020 Guidance to $300 million TEMPLE CITY, Calif., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”), a technology company providing comprehensive testing solutions through its scalable technology platform, today announced that it has updated its revenue guidance for the full year 2020 due to accelerating demand for its COVID-19 testing solutions. The company now expects to generate at least $300 million in revenue for the full year 2020, an increase of 28% compared to previous gu...

 PRESS RELEASE

Fulgent Genetics to Participate in the Credit Suisse 29th Annual Virtu...

Fulgent Genetics to Participate in the Credit Suisse 29th Annual Virtual Healthcare Conference TEMPLE CITY, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”), a technology company providing comprehensive testing solutions through its scalable technology platform, today announced that its Chief Financial Officer Paul Kim and Chief Commercial Officer Brandon Perthuis are scheduled to virtually participate in the Credit Suisse 29th Annual Virtual Healthcare Conference on Wednesday, November 11, 2020. These representatives of...

 PRESS RELEASE

Fulgent Genetics Reports Record Third Quarter 2020 Financial Results a...

Fulgent Genetics Reports Record Third Quarter 2020 Financial Results and Raises Full Year 2020 Revenue Guidance by $100 Million Third Quarter 2020 Results: Record Revenue of $101.7 million, growing more than 880% year-over-yearRecord Billable tests delivered approximately 1.04 million, growing more than 4,800% year-over-yearGross Margin improved approximately 19 percentage points sequentially and approximately 12 percentage points year-over-year; cost per test improved approximately 42% sequentiallyNon-COVID Revenue grew 57% sequentiallyBolsters reimbursement capability; revenue from reimb...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

 PRESS RELEASE

Fulgent Genetics to Announce Third Quarter 2020 Financial Results on M...

Fulgent Genetics to Announce Third Quarter 2020 Financial Results on Monday November 9, 2020 TEMPLE CITY, Calif., Oct. 26, 2020 (GLOBE NEWSWIRE) -- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”) today announced that it will release its third quarter 2020 financial results after the market closes on Monday November 9, 2020. The company’s Chairman and Chief Executive Officer Ming Hsieh, Chief Financial Officer Paul Kim and Chief Commercial Officer Brandon Perthuis will host a conference call for the investment community the same day at 4:30 PM ET (1:30 PM PT) to...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch